These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
527 related articles for article (PubMed ID: 31530667)
41. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Frias JP; Bonora E; Nevarez Ruiz L; Li YG; Yu Z; Milicevic Z; Malik R; Bethel MA; Cox DA Diabetes Care; 2021 Mar; 44(3):765-773. PubMed ID: 33397768 [TBL] [Abstract][Full Text] [Related]
42. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Wright EE; Aroda VR Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423 [TBL] [Abstract][Full Text] [Related]
43. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial. Kellerer M; Kaltoft MS; Lawson J; Nielsen LL; Strojek K; Tabak Ö; Jacob S Diabetes Obes Metab; 2022 Sep; 24(9):1788-1799. PubMed ID: 35546450 [TBL] [Abstract][Full Text] [Related]
44. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Kapitza C; Dahl K; Jacobsen JB; Axelsen MB; Flint A Diabetologia; 2017 Aug; 60(8):1390-1399. PubMed ID: 28526920 [TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Aroda VR; Aberle J; Bardtrum L; Christiansen E; Knop FK; Gabery S; Pedersen SD; Buse JB Lancet; 2023 Aug; 402(10403):693-704. PubMed ID: 37385279 [TBL] [Abstract][Full Text] [Related]
46. A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects. Xie P; Abildlund MT; Bækdal TA; He X; Lyauk YK; Patted URH; Ning Z; Shi A Diabetes Obes Metab; 2024 Aug; 26(8):3068-3077. PubMed ID: 38808476 [TBL] [Abstract][Full Text] [Related]
47. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Meier JJ Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838 [TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Frias JP; Hsia S; Eyde S; Liu R; Ma X; Konig M; Kazda C; Mather KJ; Haupt A; Pratt E; Robins D Lancet; 2023 Aug; 402(10400):472-483. PubMed ID: 37369232 [TBL] [Abstract][Full Text] [Related]
49. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Bain SC; Mosenzon O; Arechavaleta R; Bogdański P; Comlekci A; Consoli A; Deerochanawong C; Dungan K; Faingold MC; Farkouh ME; Franco DR; Gram J; Guja C; Joshi P; Malek R; Merino-Torres JF; Nauck MA; Pedersen SD; Sheu WH; Silver RJ; Tack CJ; Tandon N; Jeppesen OK; Strange M; Thomsen M; Husain M Diabetes Obes Metab; 2019 Mar; 21(3):499-508. PubMed ID: 30284349 [TBL] [Abstract][Full Text] [Related]
50. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT; JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037 [TBL] [Abstract][Full Text] [Related]
51. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB; JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259 [TBL] [Abstract][Full Text] [Related]
52. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970 [TBL] [Abstract][Full Text] [Related]
53. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A; Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376 [TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. Araki E; Terauchi Y; Watada H; Deenadayalan S; Christiansen E; Horio H; Kadowaki T Diabetes Obes Metab; 2021 Dec; 23(12):2785-2794. PubMed ID: 34472698 [TBL] [Abstract][Full Text] [Related]
55. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943 [TBL] [Abstract][Full Text] [Related]
56. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S; Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037 [TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Weinstock RS; Guerci B; Umpierrez G; Nauck MA; Skrivanek Z; Milicevic Z Diabetes Obes Metab; 2015 Sep; 17(9):849-58. PubMed ID: 25912221 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305 [TBL] [Abstract][Full Text] [Related]
59. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Husain M; Birkenfeld AL; Donsmark M; Dungan K; Eliaschewitz FG; Franco DR; Jeppesen OK; Lingvay I; Mosenzon O; Pedersen SD; Tack CJ; Thomsen M; Vilsbøll T; Warren ML; Bain SC; N Engl J Med; 2019 Aug; 381(9):841-851. PubMed ID: 31185157 [TBL] [Abstract][Full Text] [Related]
60. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. Buse JB; Bode BW; Mertens A; Cho YM; Christiansen E; Hertz CL; Nielsen MA; Pieber TR; BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33318068 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]